We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Invest in DENTSPLY SIRONA (XRAY) Stock
Read MoreHide Full Article
DENTSPLY SIRONA (XRAY - Free Report) is well poised for growth on a robust product portfolio and continued focus on research and development. However, forex remains a concern.
Shares have risen 23.5% year to date compared with the industry's 12.9% growth. The S&P 500 Index has gained 14.4% in the same time frame.
XRAY, with a market capitalization of $8.17 billion, is a global leader in the design, development, manufacturing and marketing of dental consumables, dental laboratory products, dental specialty products and consumable medical device products. It anticipates earnings to improve 9.1% over the next five years.
Image Source: Zacks Investment Research
What's Favoring the Stock?
DENTSPLY SIRONA's introduction of PrimeScan, a digital impression scanner, and Primemill, among its other major products, has been driving its top line over the past couple of years. The company bolstered its consumable areas with Surefil one, Palodent 360 and the digital denture program. Its Astra EV Implant has been gaining momentum as well.
XRAY launched Primeprint — a medical-grade, highly automated 3D printer — in 2022 to enhance dentists’ workflow and practice efficiency. Apart from being an easy-to-use device, this 3D printer enables dentists to delegate tasks related to 3D printing to their staff.
Primeprint provides complete integration with the CEREC system and enables dentists to produce night guards, surgical guides, and full-scale models in a quick and inexpensive manner.
In 2021, DENTSPLY SIRONA launched ProTaper Ultimate, which is the first major endodontic platform introduced in its endo business in more than five years. As part of a new platform, this will include new files of biosymmetric sealer and a new disinfection device.
Apart from this, the company will also introduce multiple new motor systems in the upcoming months. It will launch CEREC 5.2, a significant upgrade in Primescan, to further enhance speed and ease of use. This upgrade will support the new dental scanning capability and highlight Primescan in the marketplace.
During the first quarter of 2023, DENTSPLY SIRONA witnessed a huge demand for clear aligners, solid performance in Europe and continued strong demand for Imaging equipment.
XRAY also has an excellent new product pipeline that will aid its performance in 2023 and beyond. The company initiated a comprehensive review of its entire business in 2022 to improve execution, build a winning portfolio and return to growth. The completion of internal investigation removed a major overhang for XRAY.
What's Weighing on the Stock?
During the third quarter of 2022, DENTSPLY SIRONA recorded a non-cash charge for the impairment of goodwill and intangible assets worth $1.1 billion net of tax. The charge reflected the impact of macroeconomic factors like weakened global demand, higher cost of capital, unfavorable foreign currency impacts, and increased raw material, supply chain and service costs.
Macroeconomic headwinds, including foreign currency impacts, global supply chain challenges and regional softness continued in China and the United States.
Estimates Trend
The Zacks Consensus Estimate for 2023 revenues is pegged at $3.94 billion, indicating a 0.4% increase from the 2022 level.
The consensus mark for adjusted earnings per share is pegged at $1.91 for 2023, indicating an 8.6% year-over-year decline.
Hologic has an estimated growth rate of 5% for fiscal 2024. The company’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 27.32%.
HOLX’s shares have risen 8.4% year to date compared with the industry’s 6.4% growth.
Alcon has an estimated long-term growth rate of 14.9%. Its earnings surpassed estimates in three of the trailing four quarters and met the same once, delivering an average surprise of 8.85%.
ALC’s shares have rallied 17.2% year to date compared with the industry’s 6.4% growth.
Perrigo’s earnings are expected to improve 24.6% in 2023. The strong momentum is likely to continue in 2024 as well. PRGO’s earnings surpassed estimates in two of the trailing four quarters and missed the same twice, delivering an average negative surprise of 0.79%.
The company’s shares have lost 1.9% year to date against the industry’s 4.8% growth.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Here's Why You Should Invest in DENTSPLY SIRONA (XRAY) Stock
DENTSPLY SIRONA (XRAY - Free Report) is well poised for growth on a robust product portfolio and continued focus on research and development. However, forex remains a concern.
Shares have risen 23.5% year to date compared with the industry's 12.9% growth. The S&P 500 Index has gained 14.4% in the same time frame.
XRAY, with a market capitalization of $8.17 billion, is a global leader in the design, development, manufacturing and marketing of dental consumables, dental laboratory products, dental specialty products and consumable medical device products. It anticipates earnings to improve 9.1% over the next five years.
Image Source: Zacks Investment Research
What's Favoring the Stock?
DENTSPLY SIRONA's introduction of PrimeScan, a digital impression scanner, and Primemill, among its other major products, has been driving its top line over the past couple of years. The company bolstered its consumable areas with Surefil one, Palodent 360 and the digital denture program. Its Astra EV Implant has been gaining momentum as well.
XRAY launched Primeprint — a medical-grade, highly automated 3D printer — in 2022 to enhance dentists’ workflow and practice efficiency. Apart from being an easy-to-use device, this 3D printer enables dentists to delegate tasks related to 3D printing to their staff.
Primeprint provides complete integration with the CEREC system and enables dentists to produce night guards, surgical guides, and full-scale models in a quick and inexpensive manner.
In 2021, DENTSPLY SIRONA launched ProTaper Ultimate, which is the first major endodontic platform introduced in its endo business in more than five years. As part of a new platform, this will include new files of biosymmetric sealer and a new disinfection device.
Apart from this, the company will also introduce multiple new motor systems in the upcoming months. It will launch CEREC 5.2, a significant upgrade in Primescan, to further enhance speed and ease of use. This upgrade will support the new dental scanning capability and highlight Primescan in the marketplace.
During the first quarter of 2023, DENTSPLY SIRONA witnessed a huge demand for clear aligners, solid performance in Europe and continued strong demand for Imaging equipment.
XRAY also has an excellent new product pipeline that will aid its performance in 2023 and beyond. The company initiated a comprehensive review of its entire business in 2022 to improve execution, build a winning portfolio and return to growth. The completion of internal investigation removed a major overhang for XRAY.
What's Weighing on the Stock?
During the third quarter of 2022, DENTSPLY SIRONA recorded a non-cash charge for the impairment of goodwill and intangible assets worth $1.1 billion net of tax. The charge reflected the impact of macroeconomic factors like weakened global demand, higher cost of capital, unfavorable foreign currency impacts, and increased raw material, supply chain and service costs.
Macroeconomic headwinds, including foreign currency impacts, global supply chain challenges and regional softness continued in China and the United States.
Estimates Trend
The Zacks Consensus Estimate for 2023 revenues is pegged at $3.94 billion, indicating a 0.4% increase from the 2022 level.
The consensus mark for adjusted earnings per share is pegged at $1.91 for 2023, indicating an 8.6% year-over-year decline.
DENTSPLY SIRONA Inc. Price
DENTSPLY SIRONA Inc. price | DENTSPLY SIRONA Inc. Quote
Zacks Rank & Other Stocks to Consider
DENTSPLY SIRONA currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Hologic (HOLX - Free Report) , Alcon (ALC - Free Report) and Perrigo (PRGO - Free Report) , each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Hologic has an estimated growth rate of 5% for fiscal 2024. The company’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 27.32%.
HOLX’s shares have risen 8.4% year to date compared with the industry’s 6.4% growth.
Alcon has an estimated long-term growth rate of 14.9%. Its earnings surpassed estimates in three of the trailing four quarters and met the same once, delivering an average surprise of 8.85%.
ALC’s shares have rallied 17.2% year to date compared with the industry’s 6.4% growth.
Perrigo’s earnings are expected to improve 24.6% in 2023. The strong momentum is likely to continue in 2024 as well. PRGO’s earnings surpassed estimates in two of the trailing four quarters and missed the same twice, delivering an average negative surprise of 0.79%.
The company’s shares have lost 1.9% year to date against the industry’s 4.8% growth.